Dr. Grey AI

Anidulafungin

Peptide

Anidulafungin is a cyclic lipopeptide echinocandin antifungal for invasive candidiasis and candidemia. FDA-approved 2006. A-GRADE evidence: Phase 3 trial showed 76% success vs 60% fluconazole (P=0.01). Potent activity against Candida albicans, C. glabrata, C. tropicalis, C. krusei (MIC90 0.06-0.12 μg/ml). Crucially, 99% of fluconazole-resistant isolates remain susceptible. No hepatic or renal dose adjustment needed due to non-CYP450 metabolism - advantageous in critically ill patients. PRESCRIPTION ONLY - IV administration.

Quick Answer

What it is

Anidulafungin is a cyclic lipopeptide echinocandin antifungal for invasive candidiasis and candidemia. FDA-approved 2006.

Key findings

  • Grade A: Treatment Success (vs Fluconazole) (Candidemia and Invasive Candidiasis)
  • Grade A: Dose-Ranging Efficacy (Candidemia and Invasive Candidiasis)
  • Grade A: Activity vs Fluconazole-Resistant Candida (Candidemia and Invasive Candidiasis)

Safety

No specific caution or interaction language was detected in the current summary/outcome notes.

⚠️ Research Notice

This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.

ℹ️ Quick Facts: Anidulafungin

Quick Facts: Anidulafungin

  • Best Evidence:Grade A
  • Conditions Studied:1
  • Research Outcomes:6
  • Grade A Findings:3
  • Grade B Findings:2
  • Key Effect:Candidemia and Invasive Candidiasis
A3
B2
C1
D0
1 conditions · 6 outcomes

Detailed Outcomes

A
Treatment Success (vs Fluconazole)
Phase 3 RCT: 76% anidulafungin vs 60% fluconazole achieved treatment success (95% CI 4-27%, P=0.01). Superior efficacy in invasive candidiasis and candidemia. FDA approval 2006.
moderate↑Improves
A
Dose-Ranging Efficacy
Phase 2 study (n=123): Success rates 84%, 90%, 89% at 50, 75, 100 mg respectively. High efficacy across dose range. 100 mg daily selected for Phase 3.
large↑Improves
A
Activity vs Fluconazole-Resistant Candida
In vitro: 99% of 315 fluconazole-resistant Candida isolates susceptible to anidulafungin (MIC <=1 μg/ml). Important option for azole-resistant infections.
large↑Improves
B
Safety in Organ Impairment
No dose adjustment needed in hepatic or renal impairment. Non-CYP450 metabolism minimizes drug interactions. Well tolerated with low discontinuation rates.
moderate↑Improves
B
Antimicrobial Activity
11 human trials and systematic reviews support this finding. Evidence includes systematic reviews/meta-analyses. Human clinical trial data available.
moderate↑Improves
C
Safety/Tolerability
3 human trials support this finding. Human clinical trial data available.
small↑Improves

Research Citations (26)

Echinocandins Pharmacokinetics: A Comprehensive Review of Micafungin, Caspofungin, Anidulafungin, and Rezafungin Population Pharmacokinetic Models and Dose Optimization in Special Populations.
(2025)
PMID: 39707078
Invasive Candidiasis in Patients with Solid Tumors Treated with Anidulafungin: A Post Hoc Analysis of Efficacy and Safety of Six Pooled Studies.
(2021)
PMID: 33891293
Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm Candida albicans.
(2020)
PMID: 32363762
Anidulafungin Susceptibility Testing of Candida glabrata Isolates from Blood Cultures by the MALDI Biotyper Antibiotic (Antifungal) Susceptibility Test Rapid Assay.
(2019)
PMID: 31285227
Candida glabrata prosthetic joint infection, successfully treated with anidulafungin: A case report and review of the literature.
(2018)
PMID: 29272049
Combination antifungal therapy for invasive aspergillosis: a randomized trial.
(2015)
PMID: 25599346
Anidulafungin: advantage for the newcomer?
(2014)
PMID: 24422646
Anidulafungin for the treatment of invasive candidiasis
(2012)
PMID: 21251147
Anidulafungin: an evidence-based review of its use in invasive fungal infections
(2011)
PMID: 20862218
Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature.
(2011)
PMID: 21486730

Related Peptides

Rezafungin (Rezzayo)

Peptide

1 shared condition · 6 outcomes

Rezafungin is a second-generation cyclic lipopeptide echinocandin antifungal. FDA-approved March 2023 for candidemia and invasive candidiasis - first new echinocandin in over a decade. ReSTORE Phase 3 trial (n=199): Noninferior to caspofungin for day-14 global cure and 30-day mortality. Weekly dosing (vs daily for other echinocandins) enables outpatient treatment. Inhibits (1,3)-beta-D-glucan synthase to disrupt fungal cell wall.

Micafungin (Mycamine)

Peptide

1 shared condition · 10 outcomes

Micafungin is a cyclic lipopeptide echinocandin antifungal. FDA-approved 2005 for esophageal candidiasis, invasive candidiasis/candidemia, and uniquely for Candida prophylaxis in HSCT recipients. Clinical trials (n=3028 pooled): Favorable safety profile. Superior to fluconazole for HSCT prophylaxis. Fungicidal against Candida including fluconazole-resistant strains. Second echinocandin approved in US after caspofungin.

Caspofungin (Cancidas)

Peptide

1 shared condition · 10 outcomes

Caspofungin is a cyclic lipopeptide echinocandin - the first in its class FDA-approved (2001). Indicated for invasive candidiasis, candidemia, esophageal candidiasis, and invasive aspergillosis. Phase 2/3 trials: 85% response in esophageal candidiasis vs 67% amphotericin B. Active against fluconazole-resistant Candida (MIC90 0.5-1 ug/ml for 157 resistant isolates). Safe profile with only 2% discontinuation in RCTs. Standard comparator for newer echinocandins.